Prolonged Nerve Blockade In A Patient Treated W...

Act Ii Of The Sunshine Act

Monitoring And Evaluating Progress Towards Univ...

World's Tiniest Machine

Simeprevir For The Treatment Of Hcv Infection

0 votes
Endothelin System And Pain
Author: Terika P Smith, Tami Haymond, Sherika N Smith, Sarah M Sweitzer
15 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
ISBN/ISSN: 1178-7090
DOI: 10.2147/65923
Follow this publisher

Share this publication:


Abstract: Many people worldwide suffer from pain and a portion of these sufferers are diagnosed with a chronic pain condition. The management of chronic pain continues to be a challenge, and despite taking prescribed medication for pain, patients continue to have pain of moderate severity. Current pain therapies are often inadequate, with side effects that limit medication adherence. There is a need to identify novel therapeutic targets for the management of chronic pain. One potential candidate for the treatment of chronic pain is therapies aimed at modulating the vasoactive peptide endothelin-1. In addition to vasoactive properties, endothelin-1 has been implicated in pain transmission in both humans and animal models of nociception. Endothelin-1 directly activates nociceptors and potentiates the effect of other algogens, including capsaicin, formalin, and arachidonic acid. In addition, endothelin-1 has been shown to be involved in inflammatory pain, cancer pain, neuropathic pain, diabetic neuropathy, and pain associated with sickle cell disease. Therefore, endothelin-1 may prove a novel therapeutic target for the relief of many types of chronic pain.

Select a payment method